Latest news and press releases about Aditxt, Inc. (ADTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions.
Price
| Price | $0.01 |
| Market Cap | $5M |
| Exchange | OTC |
| Country | US |
Valuation Ratios
| Price / Book | -0.00 |
| EV / EBITDA | -0.24 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 926.02% |
| Return on Invested Capital | -406.31% |
| Return on Assets | -373.57% |
| Gross Margin | 19.89% |
| Operating Margin | -127821.37% |
| Net Margin | -362385.72% |
Related companies: AIMD · ANL · APLM · ATHA · BLRX · CTXR · GOVX
Explore sector: Healthcare · Biotechnology
More sections of ADTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks